Aurinia Pharmaceuticals annual return on equity
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Aurinia Pharmaceuticals Return on Equity (ROE) Growth & History (AUPH)
Aurinia Pharmaceuticals's return on equity was 59.91% for fiscal 2025.
View full Aurinia Pharmaceuticals company overviewAurinia Pharmaceuticals annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 59.91% | +58.39 pp |
| 2024 | 2024-12-31 | 1.52% | +21.44 pp |
| 2023 | 2023-12-31 | −19.92% | +4.54 pp |
| 2022 | 2022-12-31 | −24.46% | +16.35 pp |
| 2021 | 2021-12-31 | −40.81% | −11.74 pp |
| 2020 | 2020-12-31 | −29.07% | +11.63 pp |
| 2019 | 2019-12-31 | −40.70% | −6.85 pp |
| 2018 | 2018-12-31 | −33.85% | +32.35 pp |
| 2017 | 2017-12-31 | −66.20% | +17.13 pp |
| 2016 | 2016-12-31 | −83.33% | — |
Aurinia Pharmaceuticals quarterly return on equity
Q4.19
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 6.33% | +0.05 pp |
| Q1 2026 | 2026-03-31 | 5.98% | −0.44 pp |
| Q4 2025 | 2025-12-31 | 44.51% | +44.14 pp |
| Q3 2025 | 2025-09-30 | 9.00% | +5.19 pp |
| Q2 2025 | 2025-06-30 | 6.28% | +6.08 pp |
| Q1 2025 | 2025-03-31 | 6.42% | +9.33 pp |
| Q4 2024 | 2024-12-31 | 0.37% | +7.36 pp |
| Q3 2024 | 2024-09-30 | 3.81% | +7.24 pp |
| Q2 2024 | 2024-06-30 | 0.20% | +3.14 pp |
| Q1 2024 | 2024-03-31 | −2.92% | +3.67 pp |
| Q4 2023 | 2023-12-31 | −6.98% | −0.70 pp |
| Q3 2023 | 2023-09-30 | −3.43% | −1.31 pp |
| Q2 2023 | 2023-06-30 | −2.94% | +5.21 pp |
| Q1 2023 | 2023-03-31 | −6.59% | +1.53 pp |
| Q4 2022 | 2022-12-31 | −6.28% | +2.29 pp |
| Q3 2022 | 2022-09-30 | −2.12% | +13.82 pp |
| Q2 2022 | 2022-06-30 | −8.15% | +5.24 pp |
| Q1 2022 | 2022-03-31 | −8.12% | +4.83 pp |
| Q4 2021 | 2021-12-31 | −8.57% | −6.29 pp |
| Q3 2021 | 2021-09-30 | −15.94% | — |
| Q2 2021 | 2021-06-30 | −13.38% | — |
| Q1 2021 | 2021-03-31 | −12.95% | — |
| Q4 2020 | 2020-12-31 | −2.29% | +13.58 pp |
| Q4 2019 | 2019-12-31 | −15.87% | — |
Aurinia Pharmaceuticals return on equity trends
Over the last five fiscal years, Aurinia Pharmaceuticals's return on equity increased from −29.07% to 59.91%, a change of +88.98 percentage points. The latest reported quarter, Q2 2026, shows 6.33%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aurinia Pharmaceuticals source filings ↗